Epinephrine, Dexamethasone, and Hypertonic Saline in Bronchiolitis, Randomised Clinical Trial of Efficacy and Safety

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

In infancy, bronchiolitis is the most common acute infection of the lower respiratory Tract. The current treatment of bronchiolitis is controversial. Bronchodilators and corticosteroids are widely used but not routinely recommended. Hypertonic saline is currently the only drug recommended by the Spanish Association of Pediatrics in treatment guidelines.

The purpose of this study is quantify whether epinephrine, dexamethasone, and hypertonic saline are effective to decrease the rate of hospital admissions at seven day, also verify adverse effects in patients submitted.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital General Naval de Alta Especialidad - Escuela Medico Naval
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Epinephrine; Epinephryl borate; Racepinephrine

Criteria

Inclusion Criteria:

• Patients under 2 years of age diagnosed with bronchiolitis

• Be beneficiaries Marine

• Outpatient

• Severity of Bronchiolitis mild to moderate scale according to Wood-Downes

Exclusion Criteria:

• Patients with a history of atopy

• Patients with a history of asthma in infants

• Patients with serious bacterial illness criteria

• Patients with comorbidity